Workflow
e Laboratories (CLB)
icon
Search documents
Here's Why Core Laboratories (CLB) is a Strong Value Stock
ZACKS· 2024-09-02 14:40
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...
Is CORE LABS INC (CLB) Stock Outpacing Its Oils-Energy Peers This Year?
ZACKS· 2024-08-28 14:41
Investors interested in Oils-Energy stocks should always be looking to find the best-performing companies in the group. Is Core Laboratories (CLB) one of those stocks right now? By taking a look at the stock's year-todate performance in comparison to its Oils-Energy peers, we might be able to answer that question. Core Laboratories is one of 247 companies in the Oils-Energy group. The Oils-Energy group currently sits at #14 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector gr ...
e Laboratories (CLB) - 2024 Q2 - Quarterly Report
2024-07-25 21:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ______________ Commission File Number: 001-41695 CORE LABORATORIES INC. (Exact name of registrant as specified in its charter) Delaware 98- ...
e Laboratories (CLB) - 2024 Q2 - Earnings Call Transcript
2024-07-25 16:21
Core Laboratories Inc. (NYSE:CLB) Q2 2024 Earnings Call July 25, 2024 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Chris Hill - Chief Financial Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Conference Call Participants John Daniel - Daniel Energy Partners Stephen Gengaro - Stifel Operator Good day and welcome to the Core Laboratories Second Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note that today’s event is being ...
Core Laboratories (CLB) Q2 Earnings Surpass Estimates
ZACKS· 2024-07-24 23:10
This quarterly report represents an earnings surprise of 4.76%. A quarter ago, it was expected that this energy services company would post earnings of $0.16 per share when it actually produced earnings of $0.19, delivering a surprise of 18.75%. Core Laboratories, which belongs to the Zacks Oil and Gas - Field Services industry, posted revenues of $130.58 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 1.33%. This compares to year-ago revenues of $127.88 million. The company ...
e Laboratories (CLB) - 2024 Q2 - Quarterly Results
2024-07-24 20:37
Financial Performance - Core Laboratories reported Q2 2024 revenue of $130.6 million, with operating income of $16 million and diluted EPS of $0.19[7]. - Operating income, excluding specific items, was $16.4 million, yielding operating margins of 13%, an increase of over 100 basis points sequentially[7]. - Revenue for the six months ended June 30, 2024, was $260.2 million, a 1.6% increase from $256.2 million in 2023[23]. - Operating income decreased by 3.2% to $24.6 million compared to $25.4 million in the previous year[23]. - Net income attributable to Core Laboratories Inc. was $12.3 million, down 51.4% from $25.2 million in 2023[23]. - Diluted earnings per share (EPS) fell to $0.26, a decrease of 50.9% from $0.53 in the same period last year[23]. - Revenue for the three months ended June 30, 2024, was $130,577 million, representing a 0.7% increase from Q1 2024 and a 2.1% increase from Q2 2023[43]. - Operating income increased by 86.8% to $16,008 million compared to $8,571 million in Q1 2024, but decreased by 15.3% from $18,906 million in Q2 2023[43]. - Net income for the period was $9,190 million, a 163.3% increase from $3,490 million in Q1 2024, but a 59.9% decrease from $22,929 million in Q2 2023[43]. - Diluted earnings per share attributable to Core Laboratories Inc. was $0.19, up 171.4% from $0.07 in Q1 2024, but down 60.4% from $0.48 in Q2 2023[43]. Segment Performance - The Reservoir Description segment generated $86.3 million in revenue, up 2% sequentially and 3% year-over-year, marking six consecutive quarters of growth[8]. - Production Enhancement operations reported Q2 2024 revenue of $44.3 million, flat year-over-year, with operating income of $4.4 million[10]. - Reservoir Description segment revenue increased by 4.2% to $170.5 million, while Production Enhancement revenue decreased by 3.2% to $89.7 million[23]. - The company projects third quarter 2024 revenue for Reservoir Description to range from $86.5 million to $89.5 million[37]. Cash Flow and Debt - Free cash flow for the second quarter of 2024 was $14.3 million, with net debt reduced by $15.8 million[28]. - Net cash provided by operating activities for the six months ended June 30, 2024, was $22,676 million, indicating robust cash flow generation capabilities[49]. - As of June 30, 2024, Core's net debt was $132.3 million, reduced by $15.8 million during the quarter, with a leverage ratio of 1.66[12]. Market Outlook - Core anticipates a soft market for U.S. onshore activity for the remainder of the year, but expects growth in international and offshore services to offset declines[16]. - Core Laboratories anticipates sustainable client activity growth in international upstream projects, driven by rising crude-oil demand[36]. Equity and Assets - Total assets as of June 30, 2024, were $597.8 million, an increase of 1.7% from the previous quarter[1]. - Total equity increased to $245.7 million, reflecting a 3.5% growth compared to the prior quarter[1]. Dividends and Tax - The company declared a cash dividend of $0.01 per share, payable on August 26, 2024[13]. - The effective tax rate for the third quarter 2024 guidance is assumed to be 20%[38]. - The effective tax rate for the period was 28%, compared to 32% in Q1 2024 and a negative 46% in Q2 2023[43]. Return on Investment - Return on Invested Capital (ROIC) as of June 30, 2024, was reported at 8.0%[26].
What's in Store for Core Laboratories (CLB) in Q2 Earnings?
ZACKS· 2024-07-18 14:15
Core Laboratories Inc. (CLB) is set to release second-quarter earnings on Jul 24, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter is a profit of 22 cents per share on revenues of $133.34 million. Highlights of Q1 Earnings The Zacks Consensus Estimate for second-quarter 2024 earnings has witnessed an upward and a downward movement in the past 30 days. The estimated figure indicates a 4.76% year-over-year increase. The Zacks Consensus Estimate for revenues indicates an incr ...
Core Laboratories (CLB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ZACKS· 2024-07-17 15:08
Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 3.13% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ES ...
Core Laboratories (CLB) Up 6.2% Since Last Earnings Report: Can It Continue?
zacks.com· 2024-05-24 16:39
As of Mar 31, 2024, Core Laboratories had cash and cash equivalents of $14.9 million and long-term debt of $160.4 million. The company's debt-to-capitalization was 40.3%. A month has gone by since the last earnings report for Core Laboratories (CLB) . Shares have added about 6.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Core Laboratories due for a pullback? Before we dive into how investors and analysts have reacted ...
e Laboratories (CLB) - 2024 Q1 - Quarterly Report
2024-04-25 20:38
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ______________ Commission File Number: 001-41695 6316 Windfern Road Houston, TX 77040 (Address of principal executive offices) (Zip Code) Securities ...